Bhandari S, Allgar V, Lamplugh A, et al. - Among non-anaemic chronic kidney disease (CKD) stages 3b-5 patients with iron deficiency who were enrolled in a prospective double blinded randomised study (The Iron and the Heart Study), it was inquired if improvement in exercise capacity could be conferred by 1000 mg of intravenous (IV) iron (ferric derisomaltose (FDI)) vs placebo, when measured at 1 and 3 months post infusion. Investigators also focused on impacts on haematinic profiles and haemoglobin, safety as well as quality of life questionnaires. In this study, FDI was shown to confer a short-term beneficial impact on exercise capacity but it lacked significance although parameters of iron status were improved, haemoglobin level was maintained, and numerical increases were brought about in functional capacity and quality of life scores. There is a need for a larger study to corroborate whether intravenous iron is useful to improve the six-minute walk test in iron deficient non-anaemic non-dialysis CKD patients without heart failure.